{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T04:09:45Z","timestamp":1745554185100,"version":"3.40.4"},"reference-count":5,"publisher":"S. Karger AG","issue":"3","license":[{"start":{"date-parts":[[2003,1,1]],"date-time":"2003-01-01T00:00:00Z","timestamp":1041379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2003,1,1]],"date-time":"2003-01-01T00:00:00Z","timestamp":1041379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Chemotherapy"],"published-print":{"date-parts":[[2003]]},"abstract":"<jats:p>&lt;i&gt;Background:&lt;\/i&gt; Between January 1989 and July 1995, a prospective study of the therapeutic efficacy of the LALA 87 protocol in adult acute lymphoblastic leukaemia (ALL) has been conducted. &lt;i&gt;Methods:&lt;\/i&gt; A total of hundred and twelve patients with ALL have been analysed. The median age of the patients was 40 years (range: 15\u201365), the gender ratio (M\/F) was 66\/46, and the morphologic FAB (French-American-British) profile was L1 in 30 (26.9%) patients, L2 in 71 (63.3%) and L3 morphology in 11 (9.8%) of the patients. The LALA 87 protocol includes five phases: induction, consolidation, reinforcement, maintenance and central nervous system (CNS) prophylaxis with intrathecal methotrexate and irradiation. The induction phase comprised daunorubicin 50 mg\/m&lt;sup&gt;2&lt;\/sup&gt; (days 1\u20133), cyclophosphamide 600 mg\/m&lt;sup&gt;2&lt;\/sup&gt; (days 1 and 8), vincristine 1.5 mg\/m&lt;sup&gt;2&lt;\/sup&gt; (on days 1, 8, 15 and 22) and daily oral prednisone on days 1\u201321. Maintenance therapy was given for 2 years and consisted of different drugs as reinforcement, daily 6-mercaptopurine and weekly methotrexate. &lt;i&gt;Results:&lt;\/i&gt; Complete remission (CR) was achieved in 81 (72.3%) of the patients. The causes of induction failure were partial response in 10 (8.9%), and hypoplastic death in 12 patients (10.7%), and 9 were non-responders (8.0%). Of the 81 patients who achieved CR, 62 relapsed (76%). Among the relapsed patients, 9 developed CNS disease in spite of CNS prophylaxis during induction chemotherapy. Median follow-up for the living patients was 110 months. Median disease-free survival (DFS) was 16 months; 19 patients are still in remission with an estimated 10-year DFS (24%). Adverse prognostic factors were &gt;50 years of age, immunologic subtype and cytogenetic profile. &lt;i&gt;Conclusion:&lt;\/i&gt; The results support the strategy of applying more effort and other treatment modalities in the therapy of ALL.<\/jats:p>","DOI":"10.1159\/000070620","type":"journal-article","created":{"date-parts":[[2003,6,20]],"date-time":"2003-06-20T09:41:41Z","timestamp":1056102101000},"page":"138-145","source":"Crossref","is-referenced-by-count":3,"title":["Long-Term Survival in Acute Lymphoblastic Leukaemia in Adults Treated according to the LALA 87 Protocol"],"prefix":"10.1159","volume":"49","author":[{"given":"M.","family":"\u010colovi\u0107","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Bogdanovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Jankovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Kraguljac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Suvajd\u017ei\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2003,6,20]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199310283291801"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199310283291810"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/0165-4608(86)90178-0"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/0165-4608(90)90158-7"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/0165-4608(94)90007-8"}],"container-title":["Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/70620","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/70620","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T03:22:42Z","timestamp":1745464962000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000070620"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003]]},"references-count":5,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2003,6,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000070620","archive":["Portico"],"relation":{},"ISSN":["0009-3157","1421-9794"],"issn-type":[{"type":"print","value":"0009-3157"},{"type":"electronic","value":"1421-9794"}],"subject":[],"published":{"date-parts":[[2003]]}}}